Bioceltix S.a.
BCX.WA
Get informed when a big investor buys or sells
+ FollowMarket Cap$403.3M
Close$
$13.62
81.3% downside
Current Fair Value
81.3% downsideOvervalued by 81.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $403.30 Million |
|---|---|
| Enterprise Value | $346.64 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.03 |
| Beta | 0.91 |
| Outstanding Shares | 5,532,253 |
Return
| Return on Equity | -29.63% |
|---|---|
| Return on Assets | -28.18% |
| Return on Invested Capital | -33.11% |
Valuation & Multiples
| P/E Ratio | -20.95 |
|---|---|
| PEG | -58.55 |
| Price to Sales | - |
| Price to Book Ratio | 6.63 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -16.71 |
| Enterprise Value to Net Income | -19 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 23, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 27, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Bioceltix S.a.
46 employees
CEO: Lukasz Piotr Bzdzion Bioceltix S.A. engages in the development of stem cell-based biopharmaceuticals for veterinary use. The company’s products include BCX-CM-J, a stem-cell based biological drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, a drug...